Opioid-containing CCM included codeine monotherapy when prescribed during visits for respiratory conditions. Antihistamine recommendations were limited to visits for acute respiratory infections. Bars indicate 95% confidence intervals. Dotted line indicates the year of the public health advisory and labeling changes for pediatric CCM use.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Horton DB, Gerhard T, Strom BL. Trends in Cough and Cold Medicine Recommendations for Children in the United States, 2002-2015. JAMA Pediatr. 2019;173(9):885–887. doi:10.1001/jamapediatrics.2019.2252
Respiratory infections are extremely common pediatric illnesses, and families frequently treat children with cough and cold medicines (CCM). In 2008, the US Food and Drug Administration (FDA) recommended that children younger than 2 years not use over-the-counter (OTC) CCM given concerns about efficacy and safety.1 Soon thereafter, manufacturers voluntarily relabeled CCM for children 4 years and older,1 and the American Academy of Pediatrics recommended avoiding CCM in children younger than 6 years. Subsequent national US utilization studies through 2010 showed equivocal effects on pediatric CCM use.2,3 We studied trends over a broader timeframe in physicians’ recommendations for CCM and, for comparison, antihistamines in the US pediatric population.
This study was determined to be non–human subjects research by the Rutgers institutional review board, which did not require consent for use of fully deidentified data. We used the National Ambulatory Medical Care Surveys (2002-2015) and National Hospital Ambulatory Medical Care Surveys (2002-2015, outpatient and emergency department), nationally representative surveys of US office-based and hospital-based ambulatory settings, respectively. These yearly surveys contain cross-sectional, visit-level data on demographics, diagnoses, and medications ordered or provided at visits including recommended OTC medications. The study sample consisted of all visits for children younger than 18 years.
We measured all visits with recommendations for CCM (drugs containing antitussives, decongestants, or expectorants), subclassified by the presence of opioid ingredients (codeine or hydrocodone). We included codeine monotherapy for visits with respiratory diagnoses. Separately, we also studied single-agent antihistamines for acute respiratory infections. Single-agent antipyretics were excluded.
We conducted logistic regression analyses, with elapsed time ([Survey Year−2002]/14) as the independent variable, adjusting for covariates (Table). We examined age-specific temporal changes via a 3-way interaction between trend, era (2002-2008 vs 2009-2015), and age group. All analyses incorporated visit weights, clustering, and strata for the complex survey design. Two-sided P values less than .05 were considered statistically significant.
In a sample representing 3.1 billion pediatric visits over 14 years, US physicians ordered approximately 95.7 million CCM, of which 12.0% (sample n = 734 of 5525; 95% CI, 10.0%-14.3%) contained opioids. Recommendations for opioid-containing and nonopioid CCM declined substantially, while recommendations for antihistamines rose (Figure). After 2008, compared with older children, the trend in recommendations for nonopioid CCM appeared to decline more strongly among children younger than 2 years and among children younger than 6 years for opioid-containing CCM (Table). The trend in recommendations for antihistamines increased overall and appeared strongest in children younger than 12 years (Table). Sensitivity analyses moving the analytic cut point 1 year later did not substantively change the results (data not shown).
Experts have long questioned the safety and effectiveness of CCM in children; a 2018 review of the evidence4 validates these concerns. Our findings suggest that physicians’ recommendations of these medicines have steadily declined in the United States since 2002. These declines appeared to accelerate in children younger than 2 years after the FDA’s 2008 public health advisory, with possible replacement by increasing recommendations of offlabel antihistamines. Notably, prescriptions for opioid-containing CCM were declining before the FDA’s 2018 recommendations that all children avoid them5; these declines may have accelerated in young children after 2008. However, trends in recommendations of nonopioid CCM for children ages 2 to 6 years did not change after 2008 despite changes in labeling and the American Academy of Pediatrics’ efforts to limit such use.
Our findings are consistent with reported decreases in unintentional pediatric CCM ingestions and associated adverse events after 2008.6 Others suggested declines in CCM prescribed to children younger than 2 years but used a pre/post design without accounting for secular trends.3 Our results also contrast with prior work showing no decreases in recommendations of OTC CCM for children younger than 2 years after 20083 or in cough-associated codeine prescribing in emergency departments after 2006 professional society guidelines.2 Our study was limited by imprecision in age-specific estimates and our inability to assess actual use of CCM and antihistamines, including unfilled prescriptions and OTC drugs not recommended by physicians. Future work should investigate more recent trends in CCM use and related outcomes in pediatric populations.
Corresponding Author: Daniel B. Horton, MD, MSCE, Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, 112 Paterson St, New Brunswick, NJ 08901 (email@example.com).
Accepted for Publication: January 30, 2019.
Published Online: July 29, 2019. doi:10.1001/jamapediatrics.2019.2252
Author Contributions: Dr Horton had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Horton, Strom.
Acquisition, analysis, or interpretation of data: Horton, Gerhard.
Drafting of the manuscript: Horton.
Critical revision of the manuscript for important intellectual content: Gerhard, Strom.
Statistical analysis: Horton.
Obtained funding: Horton.
Conflict of Interest Disclosures: Dr Gerhard has consulted on unrelated matters with Eli Lilly in the past 3 years. Dr Strom has consulted on unrelated matters with Bayer, Janssen, and Sanofi in the past 3 years. No other disclosures were reported.
Funding/Support: Dr Horton is supported by award K23AR070286 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Amy L. Davidow, PhD (Rutgers School of Public Health, Piscataway, New Jersey), and Matthew T. Taylor, BA (Sidney Kimmel Medical College, Philadelphia, Pennsylvania), for input on statistical analyses; Divya Hoon, BA (Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey), for assistance with a literature search; and Molly E. Collins, MD (Fox Chase Cancer Center, Philadelphia, Pennsylvania), for editorial suggestions on the manuscript. All contributions were provided without compensation.
Create a personal account or sign in to: